Focused On-demand Library for E3 ubiquitin-protein ligase MARCHF11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

A6NNE9

UPID:

MARHB_HUMAN

Alternative names:

Membrane-associated RING finger protein 11; Membrane-associated RING-CH protein XI; RING-type E3 ubiquitin transferase MARCHF11

Alternative UPACC:

A6NNE9; A7E2S6

Background:

E3 ubiquitin-protein ligase MARCHF11, also known as Membrane-associated RING finger protein 11, plays a pivotal role in the polyubiquitination of CD4. This process is crucial for ubiquitin-dependent protein sorting, especially in developing spermatids. The enzyme operates by accepting ubiquitin from an E2 ubiquitin-conjugating enzyme and transferring it directly to targeted substrates.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase MARCHF11 could open doors to potential therapeutic strategies.